{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-013590","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.401086+00:00","generated_at":"2026-06-25T21:55:12.096267+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lyell Q1 net loss widens to $68.1M; cash $838M; LYL797 trial starts","bullets":["GAAP net loss $68.1M vs $55.0M YoY; non-GAAP net loss $50.0M vs $32.3M.","Cash, equivalents and marketable securities $838M as of March 31, 2022.","Phase 1 screening started for LYL797 (ROR1 CAR-T) in TNBC/NSCLC; initial data in 2023.","IND cleared for LYL132 (TCR therapy targeting NY-ESO-1); LYL845 TIL IND on track for H2 2022.","Appointed Gary Lee, Ph.D., as Chief Scientific Officer to lead research strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-013590","json":"https://secwatch.observer/filing/0001628280-22-013590.json","markdown":"https://secwatch.observer/filing/0001628280-22-013590.md","text":"https://secwatch.observer/filing/0001628280-22-013590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828022013590/0001628280-22-013590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828022013590/lyel-20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:55:12.096267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}